Document is current
Any future updates will be listed below
-
Authors
Piffkó, András https://orcid.org/0000-0001-5300-6594
Yang, Kaiting https://orcid.org/0000-0001-9328-5655
Panda, Arpit
Heide, Janna https://orcid.org/0000-0002-3528-1602
Tesak, Krystyna https://orcid.org/0009-0002-8421-995X
Wen, Chuangyu
Zawieracz, Katarzyna
Wang, Liangliang https://orcid.org/0000-0001-8340-5190
Naccasha, Emile Z. https://orcid.org/0009-0005-5445-9313
Bugno, Jason
Fu, Yanbin
Chen, Dapeng
Donle, Leonhard
Lengyel, Ernst https://orcid.org/0000-0001-8624-1507
Tilley, Douglas G. https://orcid.org/0000-0002-9681-3377
Mack, Matthias https://orcid.org/0000-0002-3157-7262
Rock, Ronald S. https://orcid.org/0000-0003-2188-7272
Chmura, Steven J.
Vokes, Everett E.
He, Chuan https://orcid.org/0000-0003-4319-7424
Pitroda, Sean P. https://orcid.org/0000-0003-3056-7991
Liang, Hua Laura https://orcid.org/0000-0001-5512-8595
Weichselbaum, Ralph R. https://orcid.org/0000-0002-5643-8939
- License Information
-
More Information
Article History
Received: 31 May 2023
Accepted: 8 April 2025
First Online: 14 May 2025
Competing interests
: R.R.W. has stock and other ownership interests with Boost Therapeutics, Immvira, Reflexion Pharmaceuticals, Coordination Pharmaceuticals, Magi Therapeutics and Oncosenescence. He has served in a consulting or advisory role for Aettis, Astrazeneca, Coordination Pharmaceuticals, Genus, Merck Serono S.A., Nano proteagen, NKMax America and Shuttle Pharmaceuticals. He has a patent pending entitled ‘Methods and Kits for Diagnosis and Triage of Patients with Colorectal Liver Metastases’ (PCT/US2019/028071). He has received research grant funding from Varian and Regeneron. He has received compensation including travel, accommodations, or expense reimbursement from Astrazeneca, Boehringer Ingelheim and Merck Serono S.A. C.H. has stock and other ownership interests with Accent Therapeutics and Aferna Green. C.H. is a scientific advisory board member of Aferna Green and Rona Therapeutics. A. Piffkó has consulted for Related Sciences/Danger Bio and owns equity in Danger Bio. E.L. receives research funding to study the biology of ovarian cancer from AbbVie through The University of Chicago that is unrelated to this work. A patent application has been submitted by A. Piffkó, H.L.L., S.P.P. and R.R.W and is pending at the date of publication. The other authors declare no competing interests.
